Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALT Altimmune, Inc.

Not Yet Opened 04-11 16:00:00 EDT

4.41

+0.25

+6.01%

盘后4.44

+0.03+0.68%

19:55 EDT

High4.41	Low4.12	Vol1.42M
Open4.17	D1 Closing4.16	Amplitude6.97%
Mkt Cap339.63M	Tradable Cap310.72M	Total Shares77.01M
T/O6.13M	T/O Rate2.02%	Tradable Shares70.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ALT","market":"US","secType":"STK","nameCN":"Altimmune, Inc.","latestPrice":4.41,"timestamp":1744401600000,"preClose":4.16,"halted":0,"volume":1422127,"hourTrading":{"tag":"盘后","latestPrice":4.44,"preClose":4.41,"latestTime":"19:55 EDT","volume":43745,"amount":193090.2857,"timestamp":1744415703832},"delay":0,"floatShares":70457100,"shares":77013658,"eps":-1.338795,"marketStatus":"Not Yet Opened","change":0.25,"latestTime":"04-11 16:00:00 EDT","open":4.17,"high":4.41,"low":4.12,"amount":6127739.034585,"amplitude":0.069712,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.338795,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1744617600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":4.16,"preHourTrading":{"tag":"盘前","latestPrice":4.211,"preClose":4.16,"latestTime":"09:28 EDT","volume":2519,"amount":10579.9171335,"timestamp":1744378116237},"postHourTrading":{"tag":"盘后","latestPrice":4.44,"preClose":4.41,"latestTime":"19:55 EDT","volume":43745,"amount":193090.2857,"timestamp":1744415703832},"volumeRatio":0.4601019224966293,"impliedVol":1.033,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/ALT/wiki","defaultTab":"wiki","newsList":[{"id":"2526638295","title":"Altimmune's US$42m Market Cap Fall Books Insider Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2526638295","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526638295?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 19:44","pubTimestamp":1744285445,"startTime":"0","endTime":"0","summary":"The recent price decline of 12% in Altimmune, Inc.'s  stock may have disappointed insiders who bought US$57.8k worth of shares at an average price of US$5.25 in the past 12 months. Insiders purchase with the hope of seeing their investments increase in value over time. However, due to recent losses, their initial investment is now only worth US$46.5k, which is not great.Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.The Last 12 Months Of Insider Transactions At Altimmune. In the last twelve months Altimmune insiders were buying shares, but not selling. The chart below shows insider transactions  over the last year. By clicking on the graph below, you can ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/altimmunes-us-42m-market-cap-114405522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","LU1878469433.USD","BK4139","BK4599"],"gpt_icon":0},{"id":"2525198894","title":"Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2525198894","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525198894?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 20:31","pubTimestamp":1744115460,"startTime":"0","endTime":"0","summary":"WASHINGTON, D.C., April  08, 2025  (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medici","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057618/0/en/Sixty-Degrees-Pharmaceuticals-Announces-Patent-License-Agreement-to-Advance-Development-of-Tafenoquine-for-Babesiosis-Treatment-and-Prevention-with-Yale-School-of-Medicine-and-Yale.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1878469433.USD","ALT","SXTP","BK4599","BK4139"],"gpt_icon":0},{"id":"2525834416","title":"AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2525834416","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525834416?lang=en_us&edition=full_marsco","pubTime":"2025-04-08 14:00","pubTimestamp":1744092000,"startTime":"0","endTime":"0","summary":"RINVOQ is the first and only oral Janus kinase  inhibitor approved in the European Union  to treat adult patients with giant cell arteritis . The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission 1. This marks the eighth approved indication for RINVOQ in the EU2. NORTH CHICAGO, Ill., April 8, 2025 /PRNewswire/ -- AbbVie  today announced that the European Commission  granted marketing authorization to RINVOQ  for the treatment of giant cell arteritis  in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.GCAis an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1093756168.USD","IE00B42XCP33.USD","LU1878469433.USD","CPK","LU2237443465.HKD","LU0965509101.SGD","LU1093756325.SGD","RA","SG9999015978.USD","BK4559","LU2023251221.USD","IE00BDGV0183.EUR","SG9999015986.USD","TAK","LU2129689431.USD","SG9999015945.SGD","LU2112291526.USD","IE00BJT1NW94.SGD","LU1061106388.HKD","BK4007","LU1718418525.SGD","LU1551013425.SGD","LU1162221912.USD","LU1037948897.HKD","IE0004445239.USD","LU1551013342.USD","IE00B2B36J28.USD","BK4156","LU0198837287.USD","IE00BVYPNV92.GBP","LU2087621335.USD","LU2237443895.HKD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU1003077747.HKD","LU0320765646.SGD","ALT","EC","LU0211327993.USD","LU2237443622.USD","BK4139","IE0009355771.USD","LU1934455194.USD","LU2237443978.SGD","LU0861579265.USD","LU0965508806.USD","ABBV","LU0211328371.USD","LU0234570918.USD"],"gpt_icon":0},{"id":"2524166296","title":"Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2524166296","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524166296?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 01:22","pubTimestamp":1743700920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 13:22 ET (17:22 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT"],"gpt_icon":0},{"id":"2524703490","title":"Altimmune Price Target Maintained With a $25.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2524703490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524703490?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 23:13","pubTimestamp":1743606780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2025 11:13 ET (15:13 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT"],"gpt_icon":0},{"id":"2522334487","title":"Altcoin Listings Spark Buzz in Crypto World","url":"https://stock-news.laohu8.com/highlight/detail?id=2522334487","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522334487?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 02:39","pubTimestamp":1743014363,"startTime":"0","endTime":"0","summary":"You can also read this news on BH NEWS: Altcoin Listings Spark Buzz in Crypto World. The cryptocurrency market is buzzing with excitement as exchanges roll out new altcoin listings, setting high expectations for the coming months. The recent inclusion of specific altcoins on various platforms aligns with the anticipated roadmap updates from exchanges. Just a short time ago, one prominent exchange confirmed an imminent listing, fueling further enthusiasm.The Coinbase exchange has revealed plans to support AltLayer , Pendle , and Layer3 . These altcoins, which had previously been mentioned in upcoming listings, are now officially set to be added to the exchange.In the backdrop of these developments, other significant news has surfaced. Senior officials in the EU hinted that former President Trump may consider imposing tariffs of approximately 20%, leading to a drop in Bitcoin prices. Concerns have arisen regarding potential negative impacts on consumer confidence, with Fed member Kashkar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/67e449de1ae0cc00199f5ad3/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["LU1878469433.USD","TON.USD.HKCC","APT.USD.HKCC","ALT","APT.USD.CC","BK4599","TON.USD.CC","BK4139"],"gpt_icon":0},{"id":"2522331338","title":"Coinbase to List ALT, PENDLE, and L3","url":"https://stock-news.laohu8.com/highlight/detail?id=2522331338","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522331338?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 02:22","pubTimestamp":1743013320,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 27th, Coinbase will add support for AltLayer , Pendle , and Layer3  on the Ethereum network . If liquidity conditions are met, trading will begin on March 27, 2025, at 9:00 AM Pacific Time or later. Once an adequate supply of these assets is available, the ALT-USD, PENDLE-USD, and L3-USD trading pairs will be phased in.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/287133","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["BK4144","03046","09179","COIN","09009","09046","ALT","ERC","FETH","ETH.USD.HKCC","QETH","EZET","03179","LDO.USD.HKCC","ETH.USD.CC","ETHV","03009","CETH","BK4139","BK4599","LU1878469433.USD","USD","AM"],"gpt_icon":0},{"id":"2521747128","title":"Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2521747128","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521747128?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 20:00","pubTimestamp":1742817600,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, CALIF., March 24, 2025----Kezar Life Sciences, Inc. , a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that it will present topline results from the PORTOLA Phase 2a trial evaluating zetomipzomib for the treatment of patients with autoimmune hepatitis  on Tuesday, March 25, 2025, at 8:00 a.m. ET.The event will highlight topline data from Kezar’s PORTOLA trial, a placebo-controlled, randomized, double-blind Phase 2a clinical trial evaluating the efficacy and safety of zetomipzomib in patients with AIH. Additionally, the event will feature presentations from Craig Lammert, MD, Associate Professor of Medicine at Indiana University School of Medicine and a principal investigator on the PORTOLA trial, and Gideon Hirschfield, PhD, the Lily and Terry Horner Chair in Autoimmune Liver Disease Research, and Director of the Francis Family Liver Clinic at Toronto General Hospit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kezar-life-sciences-present-topline-120000618.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4196","LU1878469433.USD","BK4599","AIH","KZR","BK4139"],"gpt_icon":0},{"id":"2521849875","title":"ALT Soars Over 18% Briefly Before Falling Back, Currently Trading at $0.038","url":"https://stock-news.laohu8.com/highlight/detail?id=2521849875","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521849875?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 02:54","pubTimestamp":1742496840,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 21st, possibly influenced by the news of \"Coinbase to Add AltLayer (ALT) to Asset Listing Roadmap,\" ALT surged over 18% briefly before falling back, currently trading at $0.038.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/286438","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["ALT","LU1878469433.USD","BK4599","BK4139"],"gpt_icon":0},{"id":"2521930734","title":"Coinbase Adds ALT, PENDLE, and L3 to Asset Listing Roadmap","url":"https://stock-news.laohu8.com/highlight/detail?id=2521930734","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521930734?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 02:53","pubTimestamp":1742496780,"startTime":"0","endTime":"0","summary":"BlockBeats News, March 21, Coinbase will add AltLayer (ALT), Pendle (PENDLE), and Layer3 (L3) to its asset listing roadmap.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//en/flash/286437","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_live","symbols":["ALT","BK4539","BK4139","BK4551","BK4599","BK4112","BK4516","BK4596","LU1861558580.USD","BK4600","COIN","BK4554","BK4595","LU1861559042.SGD","BK4535","BK4585","BK4588","LU1878469433.USD"],"gpt_icon":0},{"id":"2520458331","title":"Press Release: MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2520458331","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520458331?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:31","pubTimestamp":1742470260,"startTime":"0","endTime":"0","summary":"Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025. Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect. $16.0 Million in Cash at End of Fourth Quarter Expected to Fund the Company Into the Third Quarter of 2025. CAMBRIDGE, Mass., March 20, 2025 /PRNewswire/ -- MetaVia Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2024 and provided a corporate strategic update.Mr. Kim continued, \"In December, we reported positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . DA-1241 met the primary endpoint, achieving a reduction in alanine transaminase","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OXM","LU1878469433.USD","MTVA","BK4599","BK4139","GGT","ALT","BK4202"],"gpt_icon":0},{"id":"2520408186","title":"Altimmune Price Target Maintained With a $12.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2520408186","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520408186?lang=en_us&edition=full_marsco","pubTime":"2025-03-18 18:40","pubTimestamp":1742294400,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2025 06:40 ET (10:40 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT"],"gpt_icon":0},{"id":"2519337843","title":"Altimmune call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2519337843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519337843?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 01:45","pubTimestamp":1741974310,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Altimmune (ALT) with 13,503 calls trading, 4x expected, and implied vol increasing over 44 points to 140.99%. Mar-2...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/altimmune-call-volume-above-normal-and-directionally-bullish-23?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/altimmune-call-volume-above-normal-and-directionally-bullish-23?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALT","BK4139","LU1878469433.USD","BK4599"],"gpt_icon":0},{"id":"2519538654","title":"Altimmune Price Target Maintained With a $25.00/Share by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2519538654","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519538654?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:02","pubTimestamp":1741964520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 14, 2025 11:02 ET (15:02 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT"],"gpt_icon":0},{"id":"2519524802","title":"Altimmune Shares up 4.5% on Plans to Test Obesity Drug for Alcohol Use Disorder, Other Conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2519524802","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519524802?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 21:32","pubTimestamp":1741959122,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nFWN3PW1RK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU1878469433.USD","BK4599","ALT"],"gpt_icon":0},{"id":"2519605867","title":"BRIEF-Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519605867","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519605867?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 05:33","pubTimestamp":1741901617,"startTime":"0","endTime":"0","summary":"BRIEF-Altimmune Inc Phase 2 AUD Trial For Pemvidutide Expected In Q2 2025March 13 (Reuters) - Altimmune Inc ALT.O:ALTIMMUNE INC - PHASE 2 AUD TRIAL FOR PEMVIDUTIDE EXPECTED IN Q2 2025Further company coverage: ALT.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW1MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1878469433.USD","BK4599","ALT","BK4139"],"gpt_icon":0},{"id":"2519640188","title":"BUZZ-Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions","url":"https://stock-news.laohu8.com/highlight/detail?id=2519640188","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519640188?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 05:01","pubTimestamp":1741899701,"startTime":"0","endTime":"0","summary":"BUZZ-Altimmune gains on plans to test weight-loss drug for alcohol use disorder, other conditions** Shares of drug developer Altimmune ALT.O rose nearly 3% in extended trading before paring gains** Company says that it is planning to test its experimental weight-loss drug, pemvidutide, as a treatment for alcohol use disorder and alcohol-associated liver disease** Plans to begin a mid-stage trial in alcohol use disorder for pemvidutide in Q2 and another mid-stage trial for alcohol-related liver disease in Q3** Co's drug, pemvidutide, has shown to help patients reduce their weight by 15.6% on average in a mid-stage trial** As of the last close, stock down 27.9% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW1K2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","BK4139","ALT","LU1878469433.USD"],"gpt_icon":0},{"id":"2519869823","title":"Altimmune Inc - Phase 2 AUD Trial for Pemvidutide Expected in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2519869823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519869823?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:04","pubTimestamp":1741896289,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW1MW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALT","BK4599","BK4139","LU1878469433.USD"],"gpt_icon":0},{"id":"2518257897","title":"ALT Resources PLC Publishes Annual Report for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2518257897","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518257897?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 23:15","pubTimestamp":1741706118,"startTime":"0","endTime":"0","summary":"An update from ACP Energy PLC ( ($GB:ALTR) ) is now available. ALT Resources PLC has released its Annual Report and Accounts for the year ending Ju...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alt-resources-plc-publishes-annual-report-for-2024?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alt-resources-plc-publishes-annual-report-for-2024?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALT","LU1878469433.USD","BK4139","BK4599"],"gpt_icon":0},{"id":"2518423051","title":"Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518423051","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518423051?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 02:00","pubTimestamp":1741456800,"startTime":"0","endTime":"0","summary":"Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg. Patients treated withbaricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo. Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-baricitinib-delivered-high-rates-180000752.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-baricitinib-delivered-high-rates-180000752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B4R5TH58.HKD","LU0354030511.USD","LU2461242641.AUD","INCY","LU2602419157.SGD","BNTX","IE0002141913.USD","SG9999015945.SGD","SGXZ81514606.USD","LU0672654240.SGD","LU0198837287.USD","LU0823416689.USD","LU1061106388.HKD","SG9999017495.SGD","BK4157","LU1093756325.SGD","LU2023250504.SGD","LU2237443895.HKD","IE00BFTCPJ56.SGD","IE00BK4W5M84.HKD","ALT","BK4532","LU2237443622.USD","BK4533","LU2491049909.HKD","LU2361045086.USD","LU0471298694.HKD","LU1868836914.USD","LU2361044949.HKD","MACE","BK4548","LU1548497426.USD","RA","LU2468319806.SGD","SG9999014914.USD","ALC","LU1267930730.SGD","LLY","LU2237443978.SGD","LU0320765059.SGD","LU1720051017.SGD","LU0289739699.SGD","SG9999014880.SGD","LU1069344957.HKD","LU0203201768.USD","LU0097036916.USD","LU0471298777.SGD","LU1878469433.USD","LU2106854487.HKD","LU1023059063.AUD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.altimmune.com","stockEarnings":[{"period":"1week","weight":0.0401},{"period":"1month","weight":-0.2054},{"period":"3month","weight":-0.3581},{"period":"6month","weight":-0.3},{"period":"1year","weight":-0.475},{"period":"ytd","weight":-0.3883}],"compareEarnings":[{"period":"1week","weight":0.0567},{"period":"1month","weight":-0.0446},{"period":"3month","weight":-0.0802},{"period":"6month","weight":-0.0787},{"period":"1year","weight":0.0308},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.388889,"avgChangeRate":-0.008115},{"month":2,"riseRate":0.388889,"avgChangeRate":0.000059},{"month":3,"riseRate":0.388889,"avgChangeRate":-0.052418},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.058969},{"month":5,"riseRate":0.470588,"avgChangeRate":0.065968},{"month":6,"riseRate":0.411765,"avgChangeRate":0.016734},{"month":7,"riseRate":0.411765,"avgChangeRate":0.04705},{"month":8,"riseRate":0.411765,"avgChangeRate":0.108003},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.121386},{"month":10,"riseRate":0.222222,"avgChangeRate":0.030284},{"month":11,"riseRate":0.388889,"avgChangeRate":-0.02446},{"month":12,"riseRate":0.555556,"avgChangeRate":0.21194}],"exchange":"NASDAQ","name":"Altimmune, Inc.","nameEN":"Altimmune, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.0","shortVersion":"4.33.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Altimmune, Inc.,ALT,Altimmune, Inc.股票,Altimmune, Inc.股票老虎,Altimmune, Inc.股票老虎国际,Altimmune, Inc.行情,Altimmune, Inc.股票行情,Altimmune, Inc.股价,Altimmune, Inc.股市,Altimmune, Inc.股票价格,Altimmune, Inc.股票交易,Altimmune, Inc.股票购买,Altimmune, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Altimmune, Inc.(ALT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Altimmune, Inc.(ALT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction